Learn about BridgeBio's business model & partnering interests 

The University of Pittsburgh has launched a new partnership with BridgeBio to accelerate the development of breakthrough therapies for genetic diseases and cancers with clear genetic drivers. Pitt and BridgeBio will host an informational webinar on May 25th at 1:00 PM. BridgeBio will provide additional information regarding the company’s areas of interest, and answer questions about how the company collaborates with its academic partners.

Areas of Interest: 

• Diseases with a genetic basis – e.g., Mendelian disorders, repeat expansion diseases, cancers driven by genomic translocation or gain-of-function allele
  
  
• Therapy directly targets or compensates for the underlying genetic target – e.g., directly inhibits a gain-of-function protein, replaces a loss-of-function protein, or directly activates a homolog of the defective protein   

View one-pager for more details on the funding opportunity.

Open to Pitt faculty members.

Non-confidential proposals must be sent to Amy Phillips and are due June 21, 2021 at 5 p.m.  These proposals will be reviewed by the Innovation Institute licensing managers before submission to BridgeBio. 

[Learn more about BridgeBio.]

BridgeBio is a team of experienced drug discoverers, developers, and innovators working to create life-altering medicines that target well-characterized genetic diseases at their source.  BridgeBio was founded in 2015 to identify and advance transformative medicines to treat patients who suffer from Mendelian diseases and cancers with clear genetic drivers.

BridgeBio’s pipeline of over 17 development programs includes product candidates ranging from early discovery to late-stage development.  BridgeBio pursues sponsored research, company creation, lead investment into start-ups, and acquiring assets from pharmaceutical companies.